MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.72-year-old woman with primary cerebral lymphoma These are representative images from reference studies;...
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.50-year-old man with metastatic renal carcinoma These are representative images from reference studies;...
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.52-year-old woman with primary glioma These are representative images from reference studies; individual...
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist® (gadobutrol)1 The MERIT StudySeidl et al.48-year-old woman with non-Hodgkins lymphoma These are representative images from reference studies; individual results may vary.Reference: 1. Seidl Z,...
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Magnevist® (gadopentetate dimeglumine)1 Gerretsen et al.72-year-old man with moderate claudication in right and left thigh and calf (Fontaine stage IIb) These are representative images from reference...
Recent Comments